<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>24406361</identifier>
<setSpec>1137-6627</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Rebollo, A</dc:author>
<dc:author>Arruti, N</dc:author>
<dc:author>Alcaine, A</dc:author>
<dc:author>Mezquita, G</dc:author>
<dc:author>Andonegui, J</dc:author>
<dc:description xml:lang="en">The information available on the safety of medicines in pregnant women is limited and must be suitably channeled. Medication that is applied topically or as eye drops can present relevant systemic absorption and cross the placenta barrier or enter maternal milk. We have reviewed ophthalmic medicines according to the fetal risk categories proposed by the classification of the Food and Drug Administration (FDA). We evaluate the medicines of choice in the most frequent ophthalmic pathologies, as well as the medicines that must be avoided.</dc:description>
<dc:type>English Abstract</dc:type>
<dc:language>es</dc:language>
<dc:date>2013 Sep-Dec </dc:date>
<dc:title xml:lang="es">Uso de f√°rmacos oculares en el embarazo.</dc:title>
<dc:title xml:lang="en">[Use of ocular drugs in pregnancy].</dc:title>
<dc:publisher>Anales del sistema sanitario de Navarra</dc:publisher>
</metadata>
</record>
</pubmed-document>
